Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
March 31, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  • Roughly 1 in 3 U.S. adults have used AI to find health information, with nearly 30% seeking physical health advice and 1 in 6 turning to AI for mental health questions — making AI as common a health resource as social media, according to a new KFF poll of more than 1,300 adults.
  • More than 40% of health AI users have uploaded personal medical data — including test results and doctor’s notes — into AI tools, even as more than three-quarters of all adults say they are very or somewhat concerned about health data privacy.
  • About 1 in 5 AI health users cited inability to get an appointment or lack of a provider as a major driver — signaling that AI is increasingly filling access-to-care gaps rather than simply supplementing routine medical consultations.
  • Younger adults and low-income individuals are most likely to use AI for health questions and least likely to follow up with a provider afterward — raising concerns that AI may be widening rather than bridging healthcare equity gaps.

What Happened?

A new poll from KFF, the nonpartisan health policy research organization, finds that approximately one-third of U.S. adults have used AI tools to seek health information — a level of adoption that now rivals social media as a source of health guidance. The survey, conducted among more than 1,300 adults, found that 29% had used AI for physical health information in the past year and 1 in 6 had used it for mental health queries. The most cited reason for using AI was the desire for quick health advice, followed by researching information before a doctor’s visit. However, a significant minority — about 1 in 5 users — said they turned to AI specifically because they lacked a provider or couldn’t secure an appointment, underlining AI’s growing role as a substitute for, not just a supplement to, professional medical care. The poll also found that about 6 in 10 adults who used AI for physical health advice subsequently saw a doctor, and 4 in 10 sought a mental health professional — but younger adults were considerably less likely to make that follow-up visit.

Why It Matters?

For investors in healthcare AI and digital health, the KFF poll provides some of the most concrete market sizing data yet for the consumer health AI category. OpenAI, Microsoft, and Amazon have all launched health-specific AI tools in recent months, betting on exactly this kind of mass adoption. The 40%-plus rate of personal medical data uploads into AI tools is particularly significant: it suggests consumers are already treating these platforms as quasi-medical record repositories, creating both a competitive moat for the platforms that capture this data and a serious regulatory risk as the FTC, HHS, and state attorneys general scrutinize AI health data practices. The finding that younger, lower-income users are most likely to use AI as a primary — not supplementary — healthcare resource raises important equity and liability questions. If AI health tools give misleading or incomplete advice to populations that are least likely to follow up with a clinician, the public health consequences could be significant and the legal exposure for AI companies could be material.

What’s Next?

The health AI market is accelerating on multiple fronts simultaneously. OpenAI’s health-specific ChatGPT launched in January, Microsoft’s dedicated health AI chatbot followed in March, and Amazon expanded its health-focused AI assistant the same month — suggesting the competitive intensity will only increase. Regulatory clarity, however, is lagging: the FDA has begun scrutinizing AI clinical decision support tools but has not yet established clear standards for consumer-facing health AI. The data privacy concern flagged by KFF — more than 75% of adults worried about personal health data in AI systems — is a regulatory flashpoint that could trigger HIPAA-adjacent legislation if a major data breach occurs. For investors evaluating healthcare AI plays, the key metrics to watch are not just user numbers but follow-up care conversion rates, data upload penetration, and whether platforms can monetize the health data they’re collecting without triggering a regulatory or reputational crisis.


Source: https://www.healthcaredive.com/news/kff-poll-ai-health-information-adults/744217/

Previous Post

The Iran War’s Invisible Casualty: A Helium Crisis That Could Cripple AI Chips and MRI Scanners

Next Post

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

Recommended For You

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
4 days ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
1 week ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
1 week ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
2 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
2 weeks ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
2 weeks ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 weeks ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more

Walking After Meals Is a Simple Hack for Blood Sugar Control

by Team Lumida
2 weeks ago
woman walking on pathway during daytime

Key takeaways Powered by lumidawealth.com Just 10–15 minutes of walking after meals can lower post-meal blood sugar spikes. Light activity helps muscles absorb glucose without needing as much insulin....

Read more

Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

by Team Lumida
2 weeks ago
Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

Key takeaways Powered by lumidawealth.com India is about to become a major generic GLP-1 market, with multiple drugmakers preparing cheaper semaglutide launches after patent expiry. Prices could fall by...

Read more

Vinegar Before Meals May Help Control Blood Sugar

by Team Lumida
3 weeks ago
Several small glass bottles with orange liquid

Key takeaways Powered by lumidawealth.com 1–2 tablespoons of vinegar before meals can lower post-meal glucose spikes. Acetic acid slows carbohydrate digestion and glucose absorption. Studies show vinegar can improve...

Read more
Next Post
AI Job-Loss Panic Is Running Ahead of the Data, Says Bloomberg Opinion

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

McCormick to Buy Unilever’s $15.7B Food Empire in a Deal That Reshapes the Global Pantry

McCormick to Buy Unilever's $15.7B Food Empire in a Deal That Reshapes the Global Pantry

Related News

Bitcoin Approaches $64K Amid Memecoin Frenzy

Bitcoin Approaches $64K Amid Memecoin Frenzy

October 7, 2024
Market Watch: Fed Holds Rates, Hints at September Cut”

Fed Rate Cuts End the Era of Easy Income as Investors Move Out the Risk Curve

December 10, 2025
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

AI Infrastructure Boom Overshadows U.S. Manufacturing Revival

October 24, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018